Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Shanghai company with Celgene roots raises $360M Hong Kong IPO

By Jeff Cranmer, Executive Editor
November 21, 2020 4:11 AM UTC

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug.

Antengene Corp. Ltd. (HKEX:6996) raised HK$2.8 billion via the sale of 152.2 million shares at HK$18.08, giving the company a postmoney valuation of about HK$12 billion. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Antengene Corp. Ltd.